Evidence map›Paper›PMID 36126062›Full record

ArticlePloS one2022

Physician perceptions of drug utilization management: Results of a national survey.

Marie Louise Edwards, Perry T Yin, Michael Kuehn, Keith Bratti, Noam Kirson, Anupam B Jena, Scott Howell

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marie Louise EdwardsAnalysis Group, Inc, New York, New York, United States of America.
Perry T YinUS Pharmaceuticals, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America.
Michael KuehnAnalysis Group, Inc, New York, New York, United States of America.ORCID 0000-0001-8318-3137
Keith BrattiUS Pharmaceuticals, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America.ORCID 0000-0002-3980-3201
Noam KirsonAnalysis Group, Inc, Boston, Massachusetts, United States of America.
Anupam B JenaDepartment of Health Care Policy, Harvard Medical School, Boston, Massachusetts, United States of America.
Scott HowellUS Pharmaceuticals, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America.ORCID 0000-0003-1362-7518

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of drug utilization management techniques such as formulary exclusions, prior authorizations, and step edits has risen sharply during the last decade, contributing to the growing burden on physicians and patients. Limited quantitative data exist, however, on physician perceptions of drug utilization management. A national survey was conducted between February 9 and March 30, 2021, targeting office-based physicians working in the United States to assess their perceptions on drug utilization management in their practice. Of the 742 physicians that participated in the study, over 80% reported deciding against prescribing certain treatments in anticipation of drug utilization management at least sometimes (>50% of the time). Despite utilization management having an impact on prescribing decisions, about half of physicians said that the utilization management policies they encounter rarely or never (0-25% of the time) align with clinical evidence.

Indexed as

Drug UtilizationPhysiciansHumansPhysicians' OfficesUnited States

Identifiers

PMID36126062
PMCPMC9488785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.